行情

VRTX

VRTX

维特制药
NASDAQ

实时行情|Nasdaq Last Sale

176.00
-1.55
-0.87%
已收盘, 17:07 09/17 EDT
开盘
173.02
昨收
177.55
最高
177.82
最低
173.02
成交量
116.59万
成交额
--
52周最高
195.81
52周最低
151.80
市值
452.38亿
市盈率(TTM)
69.86
分时
5日
1月
3月
1年
5年

分析师评级

23位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

VRTX 新闻

  • The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals and Prudential Financial
  • Zacks.16小时前
  • Top Stock Reports for Celgene, Sinopec & HSBC
  • Zacks.1天前
  • How Much Are Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Insiders Taking Off The Table?
  • Simply Wall St..4天前
  • Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland
  • Zacks.4天前

更多

所属板块

生物技术和医学研究
+0.24%
制药与医学研究
+0.57%

热门股票

名称
价格
涨跌幅

VRTX 简况

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.
展开

Webull提供Vertex Pharmaceuticals Incorporated的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。